Doxorubicin (Adriamycin) Hydrochloride Mechanism of Action Review Hub

Doxorubicin (Adriamycin) Hydrochloride is a topoisomerase II (TOP2A/TOP2B) inhibitor widely investigated in DNA damage, apoptosis, and cardiotoxicity research across breast cancer, hematologic malignancies, and soft tissue sarcoma models. This hub brings together literature-reported mechanisms across diverse biological pathways and research areas, helping you explore its molecular actions.

Doxorubicin (Adriamycin) Cardiotoxicity

  1. Cardiotoxicity Mechanisms Mediated by Topoisomerase
  2. Electrophysiological and Contractile Profiling of
  3. Cardiotoxicity Attenuation via Dexrazoxane Catalytic
  4. Cardiotoxicity Driven by Sarcoplasmic
  5. Circulating Cardiac Troponin and NT-proBNP
  6. Cardiotoxicity Involving Mitochondrial Permeability Transition
  7. Cardiotoxicity Phenotyping Through Murine
  8. Cardiotoxicity Promotes Calpain-Mediated Titin Cleavage
  9. Cardiotoxicity Suppression Through Pharmacological Mitochondria-Targeted
  10. Cardiotoxicity Correlation With Cumulative Dosing
  11. Cardiotoxicity Governed by Cardiac Microvascular
  12. Cardiotoxicity Involving Nrf2 Signaling Exhaustion
  13. Quantitative Detection of Doxorubicin Cardiotoxicity
  14. Cardiotoxicity Prevention via SGLT2 Inhibitor
  15. Cardiotoxicity via Transcriptional Repression
  16. Cardiotoxicity Screening Protocols Using Engineered

Doxorubicin (Adriamycin)-Mediated DNA Damage

  1. Mediated DNA Damage Induced
  2. Mediated DNA Damage Quantification Through
  3. Mediated DNA Damage Activation
  4. Quantitative Assessment of Doxorubicin-Mediated DNA
  5. Mediated DNA Damage Repair via
  6. Mediated DNA Damage Dynamics in
  7. Mediated DNA Damage Response Orchestrated
  8. Mediated DNA Damage Sensitization
  9. Mediated DNA Damage Induction of
  10. Mediated DNA Damage Profiling Through
  11. Mediated DNA Damage Resolution Modulated
  12. Mediated DNA Damage Triggers Cytoplasmic
  13. Mediated DNA Damage Assays in
  14. Mediated DNA Intercalation Induces Selective

Multidrug Resistance

  1. Multidrug Resistance Driven by ABCB1
  2. Multidrug Resistance Reversal by Small
  3. Multidrug Resistance Driven by ABCC1
  4. Multidrug Resistance Driven by Lysosomal
  5. Multidrug Resistance Modeling Through
  6. Multidrug Resistance Mediated
  7. Multidrug Resistance Mediated by Topoisomerase
  8. Multidrug Resistance Overcoming via Dual-Delivery
  9. Multidrug Resistance Governed by MicroRNA-21
  10. Multidrug Resistance Induction
  11. Multidrug Resistance Profiling Using
  12. Multidrug Resistance Suppression by Natural
  13. Multidrug Resistance Dependent
  14. ABCB1 Disruption via Targeted CRISPR-Cas9

Doxorubicin (Adriamycin)-Induced Apoptosis

  1. Apoptosis Driving Caspase Cascade
  2. Apoptosis Detection Using Annexin
  3. Apoptosis Modulated by Bax
  4. Apoptosis Overcoming Bcl-2-Mediated Chemotherapeutic Resistance
  5. Apoptosis Triggering Mitochondrial Cytochrome
  6. Apoptosis Dissection via Real-Time Live-Cell
  7. Apoptosis Regulation by Second
  8. Apoptosis Facilitated by BID Cleavage
  9. Apoptosis Resistance Conferred
  10. Apoptosis Monitoring via Cleaved Poly(ADP-Ribose)
  11. Apoptosis Triggering Endonuclease G
  12. Apoptosis Potentiation Using Dual
  13. Apoptosis Kinetics Across Wild-Type

Oxidative Stress

  1. Oxidative Stress via Quinone Redox
  2. Driven Iron Dysregulation Amplifies Hydroxyl
  3. Targets Mitochondrial Cardiolipin to Disrupt
  4. Stimulates Inducible Nitric Oxide Synthase
  5. Activates NADPH Oxidase Complexes
  6. Resistance Modulated by Nrf2 Antioxidant
  7. Depletes Endogenous Superoxide Dismutase
  8. Oxidative Stress Activates Latent Matrix
  9. Elicits Mitochondrial Monoamine Oxidase Activation
  10. Triggers HMGB1-Dependent Inflammatory Apoptosis
  11. Biotransformation by Xanthine Oxidase Propels
  12. Oxidative Stress and Preclinical Myocardial

Breast Cancer

  1. Traps Topoisomerase II Cleavage Complexes
  2. Formulation Comparison Liposomal Delivery Diminishes
  3. Chemosensitivity Correlates with TP53 Mutation
  4. Optimizing Doxorubicin and Cyclophosphamide Regimens
  5. Resistance Mediated by Metadherin
  6. Hyaluronic Acid Nanoparticle Formulations of
  7. Cumulative Cardiotoxicity Biomarkers Identified
  8. Epirubicin in Neoadjuvant Chemotherapy
  9. Synergizes with Gambogenic Acid
  10. Pharmacokinetics Modulated by SLC22A16
  11. Triggers Mitochondrial Reactive Oxygen Species
  12. Regimen Scheduling Pathological Complete Response

Nanomedicine Delivery

  1. Nanoparticle Formulations Overcome TOP2B-Driven Cardiotoxicity
  2. PEGylated Liposomal Encapsulation of Doxorubicin
  3. Encapsulation into Ultrasmall Nanoparticles
  4. Peptide Hydrogel Sustained Elution
  5. Biodegradable Polymeric Nanoparticles Overcome P-Glycoprotein
  6. Conjugated Zeolitic Imidazolate Framework-8 Directs
  7. Carbon Nanomaterial Penetration Enhancement
  8. DNA Origami Intercalation Analysis
  9. Stimuli-Responsive Inorganic Theranostic Tracking
  10. Extracellular Vesicle Phagocytic Evasion
  11. Galactosylated Lipid Hepatocellular Delivery
  12. Prodrug Nanoparticle Antitumor Immunity

Immunogenic Cell Death

  1. Calreticulin Exposure and ATP Secretion
  2. HMGB1 Release and Dendritic Activation
  3. Synergy with Immune Checkpoint Blockade
  4. Tertiary Lymphoid Structure Formation
  5. MDSC Depletion via Redox Catastrophe
  6. Rho Kinase-Mediated T Cell Priming
  7. Caspase-1 Pyroptosis and Gasdermin Cascades
  8. Triple-Negative Breast Cancer Chemoimmunotherapy
  9. Nanoparticle Delivery and Platelet Carriers
  10. Melanoma Death Kinetics Versus Chromomycin
  11. Glioblastoma Sensitization to TLR Agonists
  12. Prophylactic Syngeneic Tumor Vaccination Assays

Hematologic Malignancies

  1. Regimen Benchmarks in Diffuse Lymphoma
  2. Rituximab Synergy in Apoptosis Induction
  3. Cytarabine Induction Protocol Comparison
  4. Cardiotoxicity Mitigation via Dexrazoxane
  5. Infusion Kinetics and Clearance Dynamics
  6. Nanomedicine Formulations with Attenuated Toxicity
  7. Kinase Inhibitor Combination for Chemoresistance
  8. Dose-Dependent Bone Marrow Suppression
  9. ROS-Mediated MAPK and p53 Signaling
  10. Cumulative Threshold Tracking for Cardioprotection

Soft Tissue Sarcoma

  1. First-Line Gemcitabine-Docetaxel Regimen Comparison
  2. Topoisomerase II and CREB3L1 Activation
  3. Cumulative Cardiotoxicity Threshold Optimization
  4. Ifosfamide Combination Antitumor Synergy
  5. Liposomal Formulation Toxicity Mitigation
  6. Albumin-Conjugated Prodrug Delivery Comparison
  7. Alveolar Soft Part Sarcoma Resistance
  8. Comparative Epirubicin Regimen Efficacy
  9. Nonextremity Sarcoma Multidrug Cytoreduction
  10. Dexrazoxane Cardioprotection in High-Dose Regimens

Cellular Senescence

  1. Endothelial G1/S Checkpoint Arrest
  2. Cardiomyocyte Mitochondrial Lactate Metabolism
  3. Vascular Smooth Muscle DNA Damage
  4. Impaired Lung Organoid Regeneration
  5. Hepatocyte UPRmt and CLPP Suppression
  6. Primary Culture G2/M Arrest
  7. Cardiomyocyte p38 MAPK Activation
  8. SIRT6 Suppression and Impaired Mitophagy
  9. Iodixanol Gradient Secretome Profiling
  10. Malignant Cell Topoisomerase IIα Poisoning

Autophagy

  1. Cardiomyocyte mTORC1 and TFEB Disruption
  2. Quantitative LC3B Lipidation Flux Assays
  3. Protective Parkin and DRP1 Mitophagy
  4. Lysosomal Neutralization in Breast Cancer
  5. AMPK Activation and Oxidative Cardiotoxicity
  6. Comparative Autophagic Vesicle Accumulation
  7. FUNDC1 Inter-Organelle Contact Disruption
  8. Beclin1 Modulation of Apoptotic Survival
  9. Dual Proteasomal and Autophagic Inhibition
  10. Macrophage Polarization via Mito-Keima Impairment

Mitochondrial Dysfunction

  1. Inner Membrane Cardiolipin Uncoupling
  2. Electron Transport Complex I Inhibition
  3. Cyclophilin D Permeability Transition
  4. Semiquinone Cycling and Superoxide Generation
  5. Comparative Myocardial Bioenergetic Failure
  6. Drp1 Mitochondrial Dynamics Disruption
  7. Bnip3 Pathway Membrane Depolarization
  8. CaMKII Mitochondrial Necroptosis Cascades

Combination Chemotherapy

  1. Docetaxel Synergy in Refractory Tumors
  2. Ifosfamide Regimens in Advanced Sarcoma
  3. Multi-Pathway Resistance in Lymphoma
  4. Trastuzumab Combinations in Breast Cancer
  5. Chemoresistance Reversal via SRC Inhibition
  6. Gastrointestinal Adenocarcinoma Chemotherapy Combinations
  7. CYP3A4 and CYP2D6 Pharmacokinetic Interactions
  8. Polymeric Nanocarrier Cardiotoxicity Attenuation

Ferroptosis

  1. Mitochondrial Iron-Driven Cardiomyocyte Ferroptosis
  2. DNAJC12-Mediated Breast Cancer Ferroptosis Evasion
  3. Neoplastic Lysis via MKK6 Repression
  4. ACSL4-Dependent Cardiac Myocyte Ferroptosis
  5. PRMT4-Mediated Inactivation of Nrf2 Signaling
  6. AIG1-Mediated Ferroptosis Alleviation Pathway
  7. Mitochondrial Ferroptosis Detection Assays
  8. Aldose Reductase-Mediated Ferroptosis Potentiation